Oxidized Zirconium (Oxinium, Smith & Nephew, Inc., Memphis, TN) is a relatively new material that features an oxidized ceramic surface chemically bonded to a tough metallic substrate. This material has demonstrated the reduced polyethylene wear characteristics of a ceramic, without the increased risk of implant fracture. The purpose of the current investigation was to assess clinical outcomes following primary total hip arthroplasty with Oxinium versus Cobalt Chrome femoral heads.

One hundred uncemented primary total hip arthroplasty procedures were prospectively performed in 100 patients. There were 52 males and 48 females with mean age at the time of surgery of 51 years (SD 11, range, 19–76). Using a process of sealed envelope randomization, patients were divided into 2 groups. Each group contained fifty patients. Those in group 1 received an Oxinium femoral head (OX), while those in group 2 a cobalt-chrome femoral head (CC).

The current study reports clinical outcome measures for both the OX and CC groups at a minimum follow-up of 2 years postoperatively. At the time of latest follow-up, stem survival for both groups was 98%. There was a significant improvement in all clinical outcome scores between preoperative and 2 year postoperative time periods for both bearing groups (p< 0.003). There were no significant differences between bearing groups for any of the clinical outcome scores at final follow-up (p> 0.159). Mean Harris Hip Scores at 2 years postoperatively were 92 and 92.5 for OX and CC, respectively (range; 65–100 OX, 60–100 CC). For SF-12, both the Physical Component Summary Scale (PCS) and the Mental Component Summary Scale (MCS) are reported. Mean PCS scores at final follow-up were 45.2 and 49.21 for OX and CC (range; 27.1–56.7 OX, 26.3–61.8 CC). Mean MCS scores were 53.8 and 52.57 for OX and CC (range; 39.2–65.5 OX, 34.3–64 CC). Mean final WOMAC scores are reported as 84.9 and 87 for OX and CC, respectively.

The current data suggest that total hip arthroplasty utilizing Oxinium femoral heads is safe and effective. Additional follow-up of the current cohort will be performed in order to fully assess mid-to long-term clinical outcomes.